33 research outputs found
Myeloid-derived suppressor cells and vaccination against pathogens
It is widely accepted that the immune system includes molecular and cellular components that play a role in regulating and suppressing the effector immune response in almost any process in which the immune system is involved. Myeloid-derived suppressor cells (MDSCs) are described as a heterogeneous population of myeloid origin, immature state, with a strong capacity to suppress T cells and other immune populations. Although the initial characterization of these cells was strongly associated with pathological conditions such as cancer and then with chronic and acute infections, extensive evidence supports that MDSCs are also involved in physiological/non-pathological settings, including pregnancy, neonatal period, aging, and vaccination. Vaccination is one of the greatest public health achievements and has reduced mortality and morbidity caused by many pathogens. The primary goal of prophylactic vaccination is to induce protection against a potential pathogen by mimicking, at least in a part, the events that take place during its natural interaction with the host. This strategy allows the immune system to prepare humoral and cellular effector components to cope with the real infection. This approach has been successful in developing vaccines against many pathogens. However, when the infectious agents can evade and subvert the host immune system, inducing cells with regulatory/suppressive capacity, the development of vaccines may not be straightforward. Notably, there is a long list of complex pathogens that can expand MDSCs, for which a vaccine is still not available. Moreover, vaccination against numerous bacteria, viruses, parasites, and fungi has also been shown to cause MDSC expansion. Increases are not due to a particular adjuvant or immunization route; indeed, numerous adjuvants and immunization routes have been reported to cause an accumulation of this immunosuppressive population. Most of the reports describe that, according to their suppressive nature, MDSCs may limit vaccine efficacy. Taking into account the accumulated evidence supporting the involvement of MDSCs in vaccination, this review aims to compile the studies that highlight the role of MDSCs during the assessment of vaccines against pathogens.Fil: Prochetto, Estefanía Soledad. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Tecnología Inmunológica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; ArgentinaFil: Borgna, Eliana Vanesa. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Tecnología Inmunológica; ArgentinaFil: Jiménez Cortegana, Carlos. Universidad de Sevilla; EspañaFil: Sánchez Margalet, Víctor. Universidad de Sevilla; EspañaFil: Cabrera, Gabriel Gustavo. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Tecnología Inmunológica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentin
Low levels of granulocytic myeloid-derived suppressor cells may be a good marker of survival in the follow-up of patients with severe COVID-19
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a
disease (coronavirus disease 2019, COVID-19) that may develop into a systemic disease with
immunosuppression and death in its severe form. Myeloid-derived suppressive cells (MDSCs)
are inhibitory cells that contribute to immunosuppression in patients with cancer and infection.
Increased levels of MDSCs have been found in COVID-19 patients, although their role in the
pathogenesis of severe COVID-19 has not been clarified. For this reason, we raised the
question whether MDSCs could be useful in the follow-up of patients with severe COVID-19 in
the intensive care unit (ICU). Thus, we monitored the immunological cells, including MDSCs, in
80 patients admitted into the ICU. After 1, 2, and 3 weeks, we examined for a possible
association with mortality (40 patients). Although the basal levels of circulating MDSCs did not
discriminate between the two groups of patients, the last measurement before the endpoint
(death or ICU discharge) showed that patients discharged alive from the ICU had lower levels
of granulocytic MDSCs (G-MDSCs), higher levels of activated lymphocytes, and lower levels of
exhausted lymphocytes compared with patients who had a bad evolution (death). In
conclusion, a steady increase of G-MDSCs during the follow-up of patients with severe
COVID-19 was found in those who eventually died
Nutrients and Dietary Approaches in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Narrative Review
Cardiovascular disease (CVD) is the most common cause of morbidity and mortality in developed countries. The prevalence of CVD is much higher in patients with type 2 diabetes mellitus (T2DM), who may benefit from lifestyle changes, which include adapted diets. In this review, we provide the role of different groups of nutrients in patients with T2DM and CVD, as well as dietary approaches that have been associated with better and worse outcomes in those patients. Many different diets and supplements have proved to be beneficial in T2DM and CVD, but further studies, guidelines, and dietary recommendations are particularly required for patients with both diseases
Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
Identification of the different elements intervening at the tumor microenvironment seems key to explain clinical evolution in several tumor types. In this study, a set of immune biomarkers (myeloid derived suppressor cells, regulatory T cells, and OX40 + and PD-1 + T lymphocytes counts) in peripheral blood of patients diagnosed with advanced breast cancer were analyzed along of first line antineoplastic therapy. Subsequently, a comparison between groups with clinical benefit versus progression of disease and with a healthy women cohort was executed. Results reflected that patients showed higher basal levels of myeloid derived suppressor cells (35.43, IR = 180.73 vs 17.53, IR = 16.96 cells/μl; p = 0.001) and regulatory T cells (32.05, IR = 29.84 vs 22.61, IR = 13.57 cells/μl; p = 0.001) in comparison with healthy women. Furthermore, an increase in the number of activated T lymphocytes (expressing OX40), a decrease of immune inhibitory cells (MDSCs and Tregs) and inhibited T lymphocytes (expressing PD-1) were observed along the treatment in patients with clinical benefit (p ≤ 0.001). The opposite trend was observed in the case of disease progression. These findings suggest that some critical immune elements can be easily detected and measured in peripheral blood, which open a new opportunity for translational research, as they seem to be correlated with clinical evolution, at least in ABC.Fundación Progreso y Salud. Junta de Andalucía (PI-0502-2014 FPS-2014
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial
Background The search for immunological markers
with ability of predicting clinical outcome is a priority in
lymphomas, and in cancer in general. It is well known
that some immunomodulatory cells, such as myeloid
derived suppressor cells (MDSCs) or regulatory T cells
(Tregs), are recruited by tumors, jeopardizing antitumor
immunosurveillance. In this work, we have studied blood
levels of these immunosuppressive cells in patients with
relapsed/refractory diffuse large B-cell lymphoma (R/R
DLBCL), prior to and along the course of the experimental
rituximab, gemcitabine, dexamethasone, and cisplatin (R2-
GDP) schedule, as a translational substudy of the R2-GDP GOTEL trial (EudraCT Number: 2014-001620-29), which
included lenalidomide as an immunomodulator.
Methods Blood samples were taken before treatment,
at cycle 3 and end of induction. Samples were analyzed
by flow cytometry. Non-parametric tests were used.
Mann-Whitney U test was used to compare basal cells
distributions, and Wilcoxon test was considered to
compare cells distribution at different times. Spearman
test was performed to measure the degree of association
between cell populations.
Results In this study, MDSC and Treg circulating
concentration was found increased in all patients
compared with a healthy control group and decreased
after treatment only in patients with longest overall
survival (>24 months), reaching the levels of the healthy group. Likewise, the number of inhibited T lymphocytes
expressing Programmed Death-1 (PD-1) were increased
in peripheral blood from patients and decreased on the
treatment, whereas activated T lymphocytes increased
after therapy in those with better overall survival.
Conclusions In conclusion, blood concentration of MDSCs
and Treg cells may be good prognostic markers for overall
survival after 2 years in R/R DLBCL. These results point to a
possible role of these elements in the immunosuppression
of these patients, as assessed by the circulating activated
and inhibited T lymphocytes, and therefore, they may be
considered as therapeutic targets in DLBCL
Nutrients and Dietary Approaches in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Narrative Review
Cardiovascular disease (CVD) is the most common cause of morbidity and mortality in
developed countries. The prevalence of CVD is much higher in patients with type 2 diabetes mellitus
(T2DM), who may benefit from lifestyle changes, which include adapted diets. In this review, we
provide the role of different groups of nutrients in patients with T2DM and CVD, as well as dietary
approaches that have been associated with better and worse outcomes in those patients. Many
different diets and supplements have proved to be beneficial in T2DM and CVD, but further studies,
guidelines, and dietary recommendations are particularly required for patients with both diseases
Estudio poblaciones celulares en pacientes con linfoma difuso de células B grandes refractarios o en recaída: papel de las células supresoras de origen mieloide en respuesta al tratamiento R2-GDP
La inmunoedición, que se caracteriza por el escape que realizan las células malignas de la inmunovigilancia antitumoral, fue reconocida hace unos años como un nuevo hallmark del cáncer. En diversos tipos de neoplasias, como el cáncer de mama o algunos linfomas, se ha comprobado cómo la infiltración linfocitaria tumoral y ciertos marcadores del perfil inmune en sangre periférica pueden suponer factores pronósticos y/o predictivos de respuesta a determinados tratamientos oncológicos.
En esta Tesis Doctoral, enmarcada en el estudio titulado “Ensayo fase II para valorar la combinación de lenalidomida con R-GDP (R2-GDP) en pacientes con linfoma difuso de células grandes B refractarios o en recaída (R/R DLBCL) no candidatos a quimioterapia a altas dosis y trasplante de células progenitoras hematopoyéticas”, se ha analizado por citometría de flujo el perfil inmune de los pacientes que padecen dicha enfermedad antes, durante y tras el tratamiento R2-GDP, basado en lenalidomida, rituximab, gemcitabina, dexametasona y cisplatino. Asimismo, los resultados obtenidos se han comparado con una cohorte de sujetos sanos que ha sido empleada como control y se han correlacionado con otros parámetros, como los subtipos de DLBCL, los niveles de vitamina D antes de iniciar el tratamiento o la tasa de respuesta objetiva.
Entre todos los parámetros del perfil inmune analizados cabe destacar las células supresoras de origen mieloide (MDSC), que comprenden un subconjunto heterogéneo de células inmaduras que, entre otras funciones, son capaces de inhibir la respuesta inmune antitumoral que ejercen los linfocitos T y promover la angiogénesis. En los últimos años, diversos estudios han demostrado altos niveles de estas células en el microambiente tumoral, por ello se ha analizado también la correlación existente en sangre periférica entre estas (y otras poblaciones celulares) con la respuesta a la terapia empleada.
Los resultados obtenidos arrojan datos prometedores de respuesta a este tratamiento para los pacientes con DLBCL que son refractarios o sufren recaídas de la terapia de primera línea. En general, con la inmunoterapia R2-GDP se ha establecido un score inmunológico en el que determinados conjuntos celulares podrían ser un posible marcador pronóstico y/o predictivo de respuesta. En particular, este tratamiento ha hecho disminuir de forma significativa el nivel de MDSC, al menos en los pacientes que han obtenido una buena respuesta, lo cual podría permitir establecer a este conjunto celular como una importante diana terapéutica contra la progresión tumoral, así como ser un potencial marcador de respuesta al tratamiento
Myeloid-derived suppressor cells and vaccination against pathogens.
It is widely accepted that the immune system includes molecular and cellular components that play a role in regulating and suppressing the effector immune response in almost any process in which the immune system is involved. Myeloid-derived suppressor cells (MDSCs) are described as a heterogeneous population of myeloid origin, immature state, with a strong capacity to suppress T cells and other immune populations. Although the initial characterization of these cells was strongly associated with pathological conditions such as cancer and then with chronic and acute infections, extensive evidence supports that MDSCs are also involved in physiological/non-pathological settings, including pregnancy, neonatal period, aging, and vaccination. Vaccination is one of the greatest public health achievements and has reduced mortality and morbidity caused by many pathogens. The primary goal of prophylactic vaccination is to induce protection against a potential pathogen by mimicking, at least in a part, the events that take place during its natural interaction with the host. This strategy allows the immune system to prepare humoral and cellular effector components to cope with the real infection. This approach has been successful in developing vaccines against many pathogens. However, when the infectious agents can evade and subvert the host immune system, inducing cells with regulatory/suppressive capacity, the development of vaccines may not be straightforward. Notably, there is a long list of complex pathogens that can expand MDSCs, for which a vaccine is still not available. Moreover, vaccination against numerous bacteria, viruses, parasites, and fungi has also been shown to cause MDSC expansion. Increases are not due to a particular adjuvant or immunization route; indeed, numerous adjuvants and immunization routes have been reported to cause an accumulation of this immunosuppressive population. Most of the reports describe that, according to their suppressive nature, MDSCs may limit vaccine efficacy. Taking into account the accumulated evidence supporting the involvement of MDSCs in vaccination, this review aims to compile the studies that highlight the role of MDSCs during the assessment of vaccines against pathogens
NK cells and solid tumors therapeutic potential and persisting obstacles
Natural killer (NK) cells, which are innate lymphocytes endowed with potent cytotoxic activity, have recently attracted attention as potential anticancer therapeutics. While NK cells mediate encouraging responses in patients with leukemia, the therapeutic effects of NK cell infusion in patients with solid tumors are limited. Preclinical and clinical data suggest that the efficacy of NK cell infusion against solid malignancies is hampered by several factors including inadequate tumor infiltration and persistence/activation in the tumor microenvironment (TME). A number of metabolic features of the TME including hypoxia as well as elevated levels of adenosine, reactive oxygen species, and prostaglandins negatively affect NK cell activity. Moreover, cancer-associated fibroblasts, tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells actively suppress NK cell-dependent anticancer immunity. Here, we review the metabolic and cellular barriers that inhibit NK cells in solid neoplasms as we discuss potential strategies to circumvent such obstacles towards superior therapeutic activity